Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Rupert

Interventional Pain Medicine Franklin, TN Medical Doctor

NPI 1124012950 CMS profile 231659

100 Covey Dr, Suite 103, Franklin, TN 37067

Open in the dashboard

General payments

$16,695

185 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Rupert of Franklin, TN is reported in the CMS Open Payments database as having received $16,695 across 185 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,370 34
2024 General $2,034 36
2023 General $9,545 42
2022 General $1,355 23
2021 General $1,320 16
2020 General $336 15
2019 General $736 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Rupert
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Matthew Rupert were reported at $1,370. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Matthew Rupert Interventional Pain Medicine median Middle half National median
2019 $736 $684 $216–$2,079 $163
2020 $336 $382 $122–$1,109 $114
2021 $1,320 $552 $167–$1,554 $132
2022 $1,355 $605 $187–$1,924 $149
2023 $9,545 $671 $195–$1,915 $160
2024 $2,034 $684 $206–$1,837 $164
2025 $1,370 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $7,434 25 payments
  2. Boston Scientific Corporation $5,439 84 payments
  3. Abbott Laboratories $1,041 42 payments
  4. MML US, Inc. $956 5 payments
  5. Medtronic, Inc. $551 8 payments
  6. SPR Therapeutics, Inc $216 3 payments
  7. Relievant Medsystems, Inc. $207 2 payments
  8. Foundation Fusion Solutions, LLC $171 2 payments
  9. Medtronic USA, Inc. $167 3 payments
  10. Vertiflex, Inc. $136 2 payments
  11. Other $378 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $8,200 6 payments
  2. Food and Beverage $5,705 169 payments
  3. Travel and Lodging $2,705 8 payments
  4. Entertainment $64 1 payment
  5. Long term medical supply or device loan $22 1 payment
Products named General payments · program years 2019–2025
  1. Evoke SCS $6,977 17 payments
  2. WaveWriter Alpha Prime 16 $5,270 81 payments
  3. ReActiv8 $956 5 payments
  4. INTELLIS ADAPTIVESTIM $551 8 payments
  5. Proclaim Family of SCS IPGs $533 16 payments
  6. Evoke $457 8 payments
  7. SPRINT PNS System $216 3 payments
  8. Intracept Pain $207 2 payments
  9. Intracept Pain $207 2 payments
  10. INTELLIS $167 3 payments
  11. Other $1,081 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

399

Median for Pain Management: 951

Drug cost

$19,135

Median for Pain Management: $26,034

Branded share of claims

31.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 42 $10,452
Fentanyl Generic 35 $3,187
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 75 $1,439
Tramadol Hcl Er Tramadol Hcl Brand 13 $1,204
Lidocaine Generic 14 $963
Gabapentin Generic 59 $647
Oxycodone Hcl Generic 25 $332
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 39 $292
Pregabalin Generic 13 $201
Tizanidine Hcl Generic 32 $188

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$88,458

Of which drugs: $218

Medicare patients

102

Average age 72

Services billed

1,137

60 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Depression 35%
Chronic kidney disease 30%
Diabetes 25%
Ischemic heart disease 21%
Osteoporosis 20%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 33 237 $181

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

185 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record